🔥Ph2 Peri-operative RASi (HRS-4642, G12D)+ GnP +/-adebrelimab (PD-L1) ➡️two cohorts n=60 #PDAC ➡️safety- mainly haem, none precluded surgery ➡️ORR 63% & 87%;MPR in 17% ➡️R0 resection rate 100% ✅6 mth EFS rate 87% & 96% ➡️100% ⬇️CA19.9; OS pending @myESMO #ESMO26 @OncoAlert

INCB161734 KRASG12D (ON/OFF) + GnP or mFFX; updated ph1, n=53 ➡️mostly GI toxicity,dose intensity 85% with GnP & 77%mFFX ✅ORR 69%, DCR 96% GnP ✅ORR 89%, DCR 100% mFFX ➡️6 mth PFS rates 80% & 90% ⭐️impressive & can combine mFFX ✅DAWN-303 ph3 ongoing @myESMO #ESMO26 @OncoAlert

Couldn’t be prouder of the amazing team I have the privilege to work with! 🤩 Thank you all for giving your very best every day for our patients and for #Oncology 🦍 @VHIO @vallhebron @GrupoGetne @myESMO @_SEOM #ESMO2026 @JHernando3 @Alej_GarciaMD @Sergioperfer

🔬 Nous avenços en #CàncerDeTiroide a #ESMO26! @Ja_Capdevila i @Alej_GarciaMD, del #VHIO, van presentar resultats dels assajos LIBRETTO-531 i SETHY, que impulsen l’oncologia de precisió i exploren noves opcions de tractament. ➡️ linke.to/ESMO2026TiroideVHIO…

#ESMO26 🧬 LIBRETTO-531 | Phase III 👥 291 pts | 1L advanced RET-mutant MTC 💊 Selpercatinib vs cabozantinib/vandetanib 📈 4-year PFS: 67.4% vs 20.5% HR 0.21 🎯 4-year OS: 87.1% vs 66.8% HR 0.34 (p<0.0001) ✅ 4-year PFS2: 85.9% vs 54.6% HR 0.23 💡 Significant OS benefit confirms selpercatinib as the preferred 1L standard! @OncoAlert

#ESMO26 Proffered Paper: NETS and endocrine tumors. “The boss”@Ja_Capdevila long term survival of Libretto-531

🇪🇸 #ESMO26 🧬 SETHY | Phase II – Spanish GETNE study 💊 Sacituzumab govitecan (TROP2 ADC) 🔬 DTC (n=24): 🎯 ORR 4.4% | mPFS 5.5 mo 🔬 ATC (n=13): 🎯 ORR 16.7% | mPFS 2.9 mo 💡 Preliminary activity in ATC. TROP2 biomarker analysis awaited! 👏 Great work by @GrupoGetne @OncoAlert

#ESMO26 ra🔬Two oral by VHIO– @Getne investigators! 🔹 @Ja_Capdevila | LIBRETTO-531: after long followup, Selpercatinib improves survival in RET-mutant medullary thyroid cancer. 🔹 @Alej_GarciaMD | SETHY @GrupoGetne : 1st anti-TROP2 ADC trial in IV thyroid cancer. 🌿Great word 🩺

#ESMO26 🚀 LIBRETTO-531 is a randomized phase 3 study comparing 1L selpercatinib vs physician’s choice of Cabozantinib or Vandetinib 🗣️ @Ja_Capdevila 📌 OS at 48m is 87.1 vs 66.8% HR 0.338 📌 PFS at 48m 67.4 vs 20.4% HR 0.205 ☣️ gran, deu mouth, diarrhea @OncoAlert @myESMO @ASCO @_SEOM @VHIO @brunolarvol 👇🏽👇🏽

#ESMO26 🚀SETHY (GETNE T2318) is a single-arm, multicenter, phase 2 trial for ATC/DTC with Sacituzumab govitecan 🗣️ @Alej_GarciaMD Congratulations on an interesting ITT trial ✔️ More efficacy at increasing H-score for #TROP2 ☣️No new safety signals Discussed by Dr. Nunes @OncoAlert @myESMO @ASCO @_SEOM @VHIO @brunolarvol 👇🏽👇🏽

🔬 New advances in #ThyroidCancer at #ESMO26! #VHIO’s @Ja_Capdevila and @Alej_GarciaMD presented findings from the #LIBRETTO-531 and #SETHY trials, supporting precision oncology and exploring new treatment options. ➡️ linke.to/ESMO2026TiroideVHIO

🔬 ¡Nuevos avances en #CáncerDeTiroides en #ESMO26! @Ja_Capdevila y @Alej_GarciaMD, del #VHIO, presentaron resultados de los ensayos LIBRETTO-531 y SETHY, que impulsan la oncología de precisión y exploran nuevas opciones de tratamiento. ➡️ linke.to/ESMO2026TiroideVHIO…

🔥Presidential session at ESMO 2026 🔥 HARMONi-GI1 ph-3: Ivonescimab + CTx vs durvalumab + CTx as 1L for BTC #ESMO26 #ESMOAmbassadors 👉ORR: 53.8 vs. 32.5 % 👉mPFS: 8.4 vs 5.8 mo 👉mOS: 14.9 vs. 12.1 mo 🧐 Very promising Chinese data, would be great to see data in a global population @myESMO @ASCO

Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial - Annals of Oncology annalsofoncology.org/article… @VHIO @vallhebron @GrupoTTD

We at @getne should be very proud of what the up-and-coming young generation is achieving. A magnificent presentation of the #CABOTHYROID study findings by @JHernando3 at #ESMO26 @myESMO @OncoAlert

#ESMO26 🇪🇸 🧬 GETNE-CABOTHYROID | Fase II presentado por @JHernando3 👥 41 pacientes | Cáncer de tiroides refractario a radioyodo 💊 Cabozantinib 🎯 ORR 25,6% 📈 SLP 16,1 meses ⏳ DoR 18,4 meses 🧬 Metilación de cfDNA: potenciales biomarcadores predictivos. 🔬 ¡Seguimos impulsando la investigación desde @GrupoGetne

🔬 The #VHIO team is at #ESMO2026! Our researchers are in Madrid to present their work, exchange ideas and connect with colleagues from across the oncology community. Looking forward to a great congress!

👏 Huge congratulations to my friend @JHernando3 on presenting the GETNE-T2216/CABOTHYROID trial at #ESMO26! Promising results with cabozantinib in advanced thyroid cancer: ORR 24%, DCR 89.7% and median PFS 16.1 months. Great work by @GrupoGetne 🇪🇸! @Ja_Capdevila @OncoAlert

Great to present the results of the @GrupoGetne SPAINTRK study at #ESMO2026! Our real-world data in spanish population support the efficacy and durability of larotrectinib across NTRK fusion-positive solid tumors. Proud of this collaborative effort!

👏👏 Amazing rapid orals session in #Neuroendocrinetumirs at #ESMO26!!!! Congratulations to the presenters and the discussants!! New Pb-based Radioligands and DLL3 driven drugs are promising new strategies in the field. @Ja_Capdevila @OncoThor @GrupoGetne @myESMO @OncoAlert @Netespana